Immunogenicity of pneumococcal vaccination after prime boosting in HIV-Infected Adults: A Randomised Controlled Trial

Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 80 个研究点目标入组 150 人开始时间: 2011年2月15日最近更新: 2014年1月27日

适应症

试验速览

暂无简介。

•Only patients who meet all of the following inclusion criteria will be eligible for enrolment into this study:
•1.Subjects must be HIV-1 infected adults with a CD4 cell count of >200cells/ml
•2.Subjects must be ARV naïve or stable on antiretroviral therapy
•3.Subjects must be free of current bacterial infection
•4.Subjects must have no history of prior pneumococcal vaccination
•5.Subject must be willing and able to understand and provide written, informed consent prior to participation in the study.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1. Pregnant women will be excluded from the study.
•2. Anyone who does not satisfy the above inclusion criteria will be excluded from the study.Immunotherapy
•3. Immunization with the PPV within the past 5 years
•4. Splenectomy
•5. Use of intravenous immunoglobulin within the past 2 months
•6. Chemotherapy or radiation
•7. Any other vaccination within the past 2 months
•8. Severe renal failure
•9. End-stage liver disease

发起方

Department of Genitourinary medicine and Infectious Diseases, St James's Hospital, Dublin 8